Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-Immunomodulatory Agents
- Development stage
- Preclinical
- Lead developer
- Alnair Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
ALN-Immunomodulatory Agents is a preclinical-stage therapeutic program developed by Alnair Therapeutics using the proprietary Alnair Lactate-reactive Nanoparticle (ALN) platform. This technology utilizes mesoporous silica nanoparticles (MSNs) designed to selectively release therapeutic payloads in the lactate-rich tumor microenvironment (TME), thereby exploiting the Warburg effect. The nanoparticles are functionalized with a lactate-reactive cap consisting of the enzyme lactate oxidase and a peroxide-sensitive linker. Upon encountering high concentrations of lactate in the TME, the enzyme converts lactate into hydrogen peroxide, which triggers the degradation of the linker and the subsequent release of the immunomodulatory payload. This program is specifically being explored for applications in photodynamic therapy (misspelled as "Polydinamic therapy" on the developer's website) to modulate anti-tumor immunity and enhance therapeutic efficacy in niche oncology indications.
- Other names
- Alnair Lactate-reactive Nanoparticle-Immunomodulatory Agents
02
Targets
L-lactate
Beyond the preview
Go deeper on ALN-Immunomodulatory Agents.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-Immunomodulatory Agents.